U.S. appeals court says Ohio cannot block Planned Parenthood funds

(Reuters) - A federal appeals court on Wednesday blocked an Ohio law that would cut federal taxpayer funding to 28 Planned Parenthood clinics, holding that conditions it imposed that denied funds to abortion providers were unconstitutional.

Gates backs gene technologies in fight to end malaria

LONDON, April 18 (Reuters) - Gene-editing technologies that alter mosquitoes' DNA could prove critical in the fight against malaria, Bill Gates said on Wednesday, and ethical concerns should not block progress in such gene-modifying research.

AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

(Reuters) - U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

Industry fears disruption as EU excludes UK from drug approvals

LONDON (Reuters) - A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients.

How healthy is too healthy? EU warns about green tea supplements

BRUSSELS (Reuters) - Taking high doses of supplements containing green tea extracts may be associated with liver damage, according to new research from the European Food Safety Authority (EFSA).

Novo Nordisk, Red Cross team up to tackle chronic diseases in conflict zones

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk and aid agency Red Cross have teamed up to try to improve the treatment of chronic diseases among the millions affected by conflicts and humanitarian crises in countries such as Syria and Yemen.

Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

LONDON (Reuters) - Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.

AI pharma firm BenevolentAI raises $115 million in funding

LONDON (Reuters) - BenevolentAI, a British pharmaceutical company that uses artificial intelligence to identify new drug candidates, said it had raised $115 million in a funding round that valued it at $2 billion. 

Later middle school start times tied to longer sleep for kids

(Reuters Health) - Starting middle school classes after 8 a.m. could help pre-teens get more sleep and be more awake during their morning lessons, a U.S. study suggests.

Cleaned endoscopes often contaminated

Many patients may be undergoing endoscopy with contaminated instruments, a pair of new studies suggest.

Related Videos

Plastic-eating enzyme holds promise in fighting pollution - scientists

Scientists in Britain and the United States say they have engineered a plastic-eating enzyme that could in future help in the fight against pollution. Stuart McDill reports.

'Urban mining' in S.Korea pulls rare battery materials from recycled tech

As China's aggressive hunt for overseas cobalt and lithium for electric vehicles pushes up prices and causes a global shortage of the key metals, South Korea is increasingly turning to such "urban mining" to recover cobalt, lithium and other scarce metals from electronic waste. Jim Drury reports.
You might like...

Check out our Reuters News Now daily briefing for hand-picked stories from Reuters editors. It's all the news you need to start your day.

Subscribe here